Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Minority Health (CHD-MH) (U54 Clinical Trial Optional)
ID: 353241Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $2M

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353241

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-020.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity for the Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Minority Health (CHD-MH), aimed at establishing a network of multidisciplinary, multi-institutional research initiatives. The program seeks to advance translational research focused on improving prevention, early detection, diagnosis, and treatment of cancer in underserved populations, particularly addressing significant health disparities. With an estimated funding amount of $80 million to support approximately four awards, each SPORE must include a minimum of three research projects targeting human endpoints, along with an Administrative Core and Shared Resources Cores. Interested applicants should note that the application submission opens on August 26, 2024, and the close date is September 26, 2024. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-020.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-CA-24-020-Full-Announcement.html
    RFA-CA-24-020.html
    The National Cancer Institute (NCI) is seeking applications for the U54 Specialized Programs of Research Excellence (SPOREs) focused on Cancer Health Disparities and Minority Health (CHD-MH). This funding opportunity aims to establish a network of multidisciplinary, multi-institutional SPOREs dedicated to advancing translational research that addresses cancer in underserved populations. Projects should emphasize improved prevention, early detection, diagnosis, and treatment of various cancer types, particularly those demonstrating significant health disparities. Eligible applicants include higher education institutions, nonprofits, and government entities, with funding totaling approximately $80 million to support an estimated four awards. Each SPORE requires a minimum of three research projects targeting human endpoints, complemented by an Administrative Core, Shared Resources Cores, and a Developmental Research Program. The application process includes strict adherence to administrative guidelines and the submission of letters of intent, with a focus on engaging community advocates and demonstrating successful collaborations. Key dates include an application submission open date of August 26, 2024, with a project period of up to five years. Overall, this initiative aims to bolster research capacity around cancer disparities, promote collaboration, and enhance translational research methodologies in underrepresented communities.
    Similar Opportunities
    Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2024, 2025, and 2026 (P50 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for Specialized Programs of Research Excellence (SPOREs) in Human Cancers, aimed at supporting innovative translational research from 2024 to 2026. This initiative invites applications for P50 Research Center Grants that focus on enhancing cancer prevention, early detection, diagnosis, and treatment, particularly for organ-specific cancers or related groups, with a requirement for at least one clinical trial component in each application. The program is crucial for advancing cancer research and addressing health disparities, with funding available up to $1,400,000 in direct costs per year over a five-year project period. Interested applicants can find more information and application guidelines at the NIH website and should direct inquiries to grantsinfo@nih.gov, with the application deadline set for September 25, 2026.
    Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Basic Research in Cancer Health Disparities" under the R21 Exploratory/Developmental Research Grant mechanism. This initiative aims to support innovative research investigating the biological and genetic factors contributing to cancer health disparities among various racial and ethnic populations, with a focus on mechanistic studies and the development of new methodologies. The program is designed to foster collaboration among scientists and build a nationwide cohort dedicated to advancing the understanding of cancer disparities, ultimately leading to future R01 projects. Applications can be submitted starting September 16, 2024, with a budget cap of $275,000 over two years, and the closing date for submissions is November 16, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE)" aimed at fostering collaborations between institutions serving underserved populations and NCI-designated Cancer Centers. The initiative seeks to enhance cancer research capacity, promote workforce diversity, and implement community outreach initiatives to address cancer health disparities. This program is vital for developing comprehensive research projects that include administrative cores, research education, and outreach efforts, ultimately contributing to a stronger national cancer program. Eligible applicants can request funding of up to $2.2 million over five years, with the application submission period starting on December 15, 2023. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced the "Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research" (R21 Clinical Trial Not Allowed). This funding opportunity aims to enhance diversity among early-stage and junior investigators in cancer research, particularly from groups that are underrepresented in the biomedical, behavioral, clinical, and social sciences. The initiative encourages innovative studies in cancer biology, with a maximum funding amount of $275,000 available over a two-year period, and applications must demonstrate scientific merit and innovation. The application window opens on May 17, 2024, with the first awards expected to be made in June 2024; interested applicants can find more information and submission guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Administrative Supplements to Support Cancer Disparity Collaborative Research (Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced an Administrative Supplement funding opportunity aimed at enhancing cancer disparities research through the initiative PAR-22-114. This program encourages collaborations between seasoned cancer researchers and those focused on cancer disparities, with the goal of addressing adverse differences in cancer outcomes among racial/ethnic minorities and underserved populations. The funding supports the expansion of existing NCI-funded research projects to include feasibility studies on various cancer types, with a total funding amount of $2.55 million available for up to 10 awards, each with a budget limit of $150,000 in direct costs over a 12-month period. Interested applicants must submit their proposals by January 23, 2025, and can direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities" (R01, Clinical Trial Required). This initiative aims to solicit applications for projects that identify and address barriers to cancer screening and preventive services, particularly in underserved populations, through multi-level interventions involving patients, clinicians, healthcare settings, and community partners. The focus is on developing evidence-based strategies to improve cancer outcomes for groups such as Black Americans, Hispanics, and Native Americans, emphasizing health equity and structured research methodologies. Interested applicants can find more details and submit proposals by January 7, 2027, with the first application due date being October 5, 2023. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov, and further information is available at NIH Grants.
    NIMHD Exploratory/Developmental Research Grant Program (R21 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NIMHD Exploratory/Developmental Research Grant Program (R21 - Clinical Trial Optional) to support innovative research aimed at addressing minority health and health disparities in the United States. This grant invites applications for short-term exploratory projects that can either pioneer new advancements or build upon previous findings, with a maximum funding amount of $275,000 available for a two-year project period, limiting annual requests to $200,000. The program emphasizes the importance of diverse representation among applicants and encourages partnerships with relevant stakeholders, focusing on NIH-designated health disparity populations through various research methodologies. Interested applicants can find more information and submission guidelines at the provided link, with the application deadline set for May 7, 2026. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Community Level Interventions to Improve Minority Health and Reduce Health Disparities (R01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Community Level Interventions to Improve Minority Health and Reduce Health Disparities" (R01 - Clinical Trial Optional), aimed at supporting research that develops and tests community-level interventions to enhance minority health and mitigate health disparities. Applicants are encouraged to form collaborative partnerships with community organizations and must focus on innovative, sustainable initiatives that address health disparities through community-level determinants, employing a conceptual model to connect interventions with health outcomes. The grant provides up to $1 million in direct costs per year for a project duration of up to five years, with applications due by January 7, 2027. For further information, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-231.html.
    Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research," aimed at advancing cancer research through the use of the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Biorepository. This initiative encourages applications that leverage high-quality, pre-diagnostic biospecimens and associated data to explore cancer risk factors and develop early detection biomarkers, emphasizing the unique characteristics of the PLCO resources. Eligible applicants include a diverse range of institutions, including historically black colleges, tribal colleges, and various community organizations, with no cost-sharing requirement. The application deadline is October 11, 2024, and interested parties can find more information and contact details at the NIH website or via email at OERWebmaster03@od.nih.gov.